ImmunityBio Securities Law Investigation
Analysis based on 9 articles · First reported Apr 14, 2026 · Last updated Apr 20, 2026
The investigation and potential lawsuit against ImmunityBio for alleged securities law violations are likely to negatively impact its stock price and investor confidence. This event highlights the risks associated with corporate disclosures and can lead to increased scrutiny of other biotechnology companies' product claims.
Lowey Dannenberg P.C. is investigating ImmunityBio for potential violations of federal securities laws. A complaint was filed on March 26, 2026, alleging that ImmunityBio and its officer, Patrick Soon-Shiong, misrepresented and overstated the capabilities of Anktiva. This has led to concerns that ImmunityBio's statements about its business, operations, and prospects were materially false and misleading. Lowey Dannenberg is seeking investors who suffered losses in ImmunityBio securities to participate in the investigation.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard